Baidu
map

盘点:近期关于抗甲状腺药物研究进展一览

2017-12-23 lishiting MedSci原创

【1】JCEM:甲状腺激素抵抗的产前诊断及临床意义甲状腺激素β抵抗(RTHβ)是一种常染色体显性遗传疾病,其主要特点是靶组织对甲状腺激素(TH)敏感性的下降。RTHβ的患者因为TH受体β基因(THRβ)的突变而表现为TH高水平。孕期RTHβ的管理很有难度,因为RTHβ母亲所生的野生型(WT)胎儿由于宫内暴露于TH过量,会出现出生低体重和出生后的TSH抑制。为了确定出生体重与fT4低于正常值上限(U

【1】JCEM:甲状腺激素抵抗的产前诊断临床意义

甲状腺激素β抵抗(RTHβ)是一种常染色体显性遗传疾病,其主要特点是靶组织对甲状腺激素(TH)敏感性的下降。RTHβ的患者因为TH受体β基因(THRβ)的突变而表现为TH高水平。孕期RTHβ的管理很有难度,因为RTHβ母亲所生的野生型(WT)胎儿由于宫内暴露于TH过量,会出现出生低体重和出生后的TSH抑制。

为了确定出生体重与fT4低于正常值上限(ULN)20%的RTHβ母亲所生的WT胎儿生后TSH的关系,近日在JCEM上发表的一篇文章进行了一项回顾性图表分析。该研究对13例有THRβ基因突变的妇女18次妊娠进行了评估,利用羊膜腔穿刺进行产前基因诊断。为了避免血清fT4高于ULN的20%,怀有WT胎儿的妇女给予了抗甲状腺药物治疗。

该研究结果显示RTHβ母亲所生的WT和 RTHβ 婴儿在 出生体重和出生时血清TSH水平上无明显差异。

产前诊断在孕期RTHβ管理中发挥重要作用。孕有WT胎儿的RTHβ母亲使其fT4水平不高于ULN的50%可能是防止其他低体重出生和出生后TSH抑制的一个好方法。(原文详见--JCEM:甲状腺激素抵抗的产前诊断及临床意义)

【2】Sci Rep:科研人员发现中国北方汉族人 抗甲状腺药物导致粒细胞缺乏相关致病基因

甲亢是临床中的常见病与多发病,抗甲状腺药物(ATD)长期以来都被认为是治疗甲亢的有效方法。应用抗甲状腺药物绝大部分需要长疗程,一般至少2年。临床中少数患者在使用抗甲状腺药物后会发生比较严重的副作用,比如粒细胞缺乏、肝损伤,这也是长期以来甲亢治疗的主要问题之一。

近日,西安交大一附院内分泌科施秉银教授团队贺雅毅博士的论文"Association of HLA-B and HLADRB1 polymorphisms with antithyroid drug-induced agranulocytosis in a Han population from northern China"在Scientific Reports杂志上发表。该研究纳入了29例服用ATD后发生粒细胞缺乏的甲亢患者和140例服用ATD后粒细胞正常的患者,对他们进行了HLA分型检测。结果发现HLA-B*27:05,HLA-B*38:02及HLA-DRB1*08:03与抗甲状腺药物导致粒细胞缺乏症相关,也就是说携带这些基因的患者给予抗甲状腺药物治疗很可能会发生粒缺。目前关于抗甲状腺药物导致粒细胞缺乏易感基因存在地区和种族差异,目前关于这方面研究非常有限。本研究是在中国北方汉族人群中的首次报道,对于揭示抗甲状腺药物治疗导致粒细胞缺乏症的遗传因素有非常重要的价值。

此类研究发现可以提示,治疗前如果通过相关基因的检测可以预测出哪些患者可能发生粒缺,对此部分患者在采用抗甲状腺药物治疗时,就应加强监测以应对可能发生的情况,必要时选择其他有效治疗方案。该研究从遗传学角度解释抗甲状腺药物治疗导致粒细胞缺乏的相关机制,对于提高甲亢临床治疗的精准化,个体化治疗提供新的治疗思路。(原文详见--Sci Rep:科研人员发现中国北方汉族人 抗甲状腺药物导致粒细胞缺乏相关致病基因)

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2035041, encodeId=edc02035041b5, content=<a href='/topic/show?id=ad5955450d7' target=_blank style='color:#2F92EE;'>#抗甲状腺药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55450, encryptionId=ad5955450d7, topicName=抗甲状腺药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Fri Aug 10 04:04:00 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380932, encodeId=8de6138093280, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon Dec 25 10:04:00 CST 2017, time=2017-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=272006, encodeId=fc0c2e200640, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Sun Dec 24 07:06:09 CST 2017, time=2017-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=271910, encodeId=41ee2e191072, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Sat Dec 23 19:28:43 CST 2017, time=2017-12-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2035041, encodeId=edc02035041b5, content=<a href='/topic/show?id=ad5955450d7' target=_blank style='color:#2F92EE;'>#抗甲状腺药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55450, encryptionId=ad5955450d7, topicName=抗甲状腺药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Fri Aug 10 04:04:00 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380932, encodeId=8de6138093280, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon Dec 25 10:04:00 CST 2017, time=2017-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=272006, encodeId=fc0c2e200640, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Sun Dec 24 07:06:09 CST 2017, time=2017-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=271910, encodeId=41ee2e191072, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Sat Dec 23 19:28:43 CST 2017, time=2017-12-23, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2035041, encodeId=edc02035041b5, content=<a href='/topic/show?id=ad5955450d7' target=_blank style='color:#2F92EE;'>#抗甲状腺药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55450, encryptionId=ad5955450d7, topicName=抗甲状腺药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Fri Aug 10 04:04:00 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380932, encodeId=8de6138093280, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon Dec 25 10:04:00 CST 2017, time=2017-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=272006, encodeId=fc0c2e200640, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Sun Dec 24 07:06:09 CST 2017, time=2017-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=271910, encodeId=41ee2e191072, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Sat Dec 23 19:28:43 CST 2017, time=2017-12-23, status=1, ipAttribution=)]
    2017-12-24 三生有幸9135

    学习一下谢谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2035041, encodeId=edc02035041b5, content=<a href='/topic/show?id=ad5955450d7' target=_blank style='color:#2F92EE;'>#抗甲状腺药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55450, encryptionId=ad5955450d7, topicName=抗甲状腺药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Fri Aug 10 04:04:00 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380932, encodeId=8de6138093280, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon Dec 25 10:04:00 CST 2017, time=2017-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=272006, encodeId=fc0c2e200640, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Sun Dec 24 07:06:09 CST 2017, time=2017-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=271910, encodeId=41ee2e191072, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Sat Dec 23 19:28:43 CST 2017, time=2017-12-23, status=1, ipAttribution=)]
    2017-12-23 131****1460

    学习了受益匪浅

    0

相关资讯

JCEM:抗甲状腺药物治疗GD复发率高

有多种治疗方案可用于Graves病(GD),包括抗甲状腺药物(ATDs)、放射性碘(RAI)和甲状腺切除术。为了确定各种治疗方案的复发率,以及现有的关于ATDs不良反应的数据,来自美国马约诊所Rebecca S Bahn教授及其团队进行了一项研究,该研究发现ATDs治疗GD复发率高。该研究结果在线发表在2013年7月3日的《临床内分泌代谢杂志》(The journal of clinical en

王建华:基层医生常见的甲亢诊治误区

甲亢是仅次于糖尿病的第二大常见内分泌疾病,如果控制不利,可以导致全身多个系统(如神经、循环、消化等)的功能损害。本病治疗主要分为药物治疗、放射性碘治疗和手术治疗,至于采取哪种方法主要根据患者的具体病情和国情而定。近年来,随着经济的高速发展和生活节奏的加快,人们精神压力越来越大,再加上环境辐射增多以及碘摄入不合理(缺碘或高碘)等因素,使得甲亢的发病率明显增加,根据最新的《中国十城市甲状腺病流

Expert Opin Drug Saf:抗甲状腺药物会否诱发急性精神障碍尚无定论

近期BioPortfolio.com收载的一篇文章对有关应用抗甲状腺药物(ATDs)引起精神疾病的文献进行了回顾,并请专家对此进行了点评。ATDs临床用于甲状腺功能亢进的治疗,曾有少量报道称无精神病史的患者在应用ATDs后突发急性精神障碍。 作者认为,在应用因放射免疫鉴定法检测促甲状腺激素(TSH)和甲状腺激素的技术发明前,因使用ATD而诱发急性精神疾病的病例较为罕见,且大多数为多年前的报道

Baidu
map
Baidu
map
Baidu
map